DOCSLIB.ORG

A Molecular Approach to Breast Imaging

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Molecular Approach to Breast Imaging Journal of Nuclear Medicine, published on January 16, 2014 as doi:10.2967/jnumed.113.126102 FOCUS ON MOLECULAR IMAGING A Molecular Approach to Breast Imaging Amy M. Fowler Department of Radiology, University of Wisconsin–Madison, Madison, Wisconsin malignant cells. A recent meta-analysis of the accuracy of 99mTc-sestamibi scintimammography as an adjunct to di- Molecular imaging is a multimodality discipline for noninvasively agnostic mammography for detection of breast cancer dem- visualizing biologic processes at the subcellular level. Clinical applications of radionuclide-based molecular imaging for breast onstrated a sensitivity of 83% and specificity of 85% (2). cancer continue to evolve. Whole-body imaging, with scinti- However, sensitivity was less for nonpalpable (59%) versus mammography and PET, and newer dedicated breast imaging palpable lesions (87%) despite comparable specificity, with systems are reviewed. The potential clinical indications and the no significant difference between planar and SPECT meth- challenges of implementing these emerging technologies are ods. Decreased sensitivity for nonpalpable, presumably presented. smaller, lesions is in part due to the limited spatial resolu- Key Words: molecular imaging; oncology; breast; PET; PET/ tion of conventional g cameras. CT; radiopharmaceuticals; breast cancer; breast-specific g im- In addition to 99mTc-sestamibi, the positron-emitting ra- aging; positron-emission mammography; positron-emission to- diopharmaceutical 18F-FDG accumulates in many types of mography cancer including breast. Meta-analyses of the accuracy of J Nucl Med 2014; 55:1–4 whole-body 18F-FDG PET used after standard diagnostic DOI: 10.2967/jnumed.113.126102 workup for patients with suspected breast lesions demon- strated sensitivities of 83%–89% and specificities of 74%– 80% (3,4). For patients with newly diagnosed biopsy- Molecular imaging allows noninvasive visualization of proven breast cancer, the sensitivity of combined PET/CT the underlying pathobiology of cancer. It holds promise was 87% (5,6). However, sensitivity is less than 50% for for personalized medicine by detecting the presence of specific small (#1 cm), low-grade invasive cancers and ductal car- biologic targets used to tailor therapy and predict outcome. cinoma in situ (DCIS). Thus, current recommendations do Additionally, molecular imaging can be beneficial for new not support the routine use of 18F-FDG PET for primary drug development using an imaging parameter to serve as breast cancer diagnosis because of its false-negative risk a surrogate endpoint for survival in clinical trials, saving and have encouraged the development of dedicated breast time and cost. This article concentrates on the clinical appli- PET scanners with improved spatial resolution for imaging cations of molecular imaging for breast cancer, focusing on small, clinically relevant, cancers (4). radionuclide techniques. Single-Photon g Imaging Systems for Dedicated TYPES OF MOLECULAR IMAGING USED FOR Breast Imaging BREAST CANCER For this review, dedicated breast imaging systems The potential for molecular imaging of breast cancer was designed for single-photon-emitting radiopharmaceuticals discovered serendipitously in the 1970s when single-photon- will be collectively referred to as breast-specific g imaging emitting radiopharmaceuticals administered for bone and (BSGI). These systems use standard mammographic posi- cardiac imaging also localized within breast malignancies tioning (craniocaudal and mediolateral oblique) with the (1). Further investigations of planar scintigraphy and SPECT breast in direct contact with the g camera. They differ of the breast, termed scintimammography, have focused primar- mainly by the type (scintillation crystal vs. semiconductor) ily on 99mTc-methoxyisobutylisonitrile (99mTc-sestamibi). and configuration (single vs. dual) of the detector (7). Com- 99mTc-sestamibi accumulation in cancer reflects in- mercially available BSGI systems include the Dilon 6800 creased vascularity and concentration of mitochondria in (Dilon Diagnostics), LumaGEM (Gamma Medica), and Discovery NM750b (GE Healthcare). 99mTc-sestamibi is the only single-photon-emitting radio- Received Oct. 1, 2013; revision accepted Dec. 19, 2013. For correspondence or reprints contact: Amy M. Fowler, Department of pharmaceutical that has approval from the Food and Drug Radiology, University of Wisconsin–Madison, 600 Highland Ave., Madison, Administration (FDA) for breast imaging. It is approved as WI 53792-3252. E-mail: [email protected] a diagnostic tool after mammography and is not indicated Published online nnnnnnnnnnnn. for screening or as an alternative to biopsy. Typical proto- COPYRIGHT ª 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc. cols specify an injection of 740–1,100 MBq (20–30 mCi) AMOLECULAR APPROACH TO BREAST IMAGING • Fowler 1 jnm126102-pm n 1/10/14 Copyright 2014 by Society of Nuclear Medicine. into the arm contralateral to the suspected abnormality. with suspected breast lesions yielded a sensitivity of 87% Imaging begins 5–10 min after injection, with 10 min per view. and specificity of 85% (1). Sensitivities for subcentimeter A meta-analysis of the accuracy of BSGI as an adjunct to cancers and DCIS were 73% and 88%, respectively, which mammography for breast cancer detection in both the exceed those previously reported for whole-body PET. Fur- diagnostic and the high-risk screening settings demon- thermore, several studies confirmed the improved sensitiv- strated a sensitivity of 95% and specificity of 80% (8). ity of PEM (92%–95%) when directly compared with Sensitivity decreased for subcentimeter cancers (84%) whole-body PET (56%–68%) or PET/CT (87%) obtained and DCIS (88%) but was improved compared with prior after a single injection of 18F-FDG (Fig. 1) (5,6,11). Thus, ½Fig: 1 reports of conventional scintimammography. Common the proposed advantage of dedicated breast imaging in causes of false-positives included fibrocystic changes, detecting small cancers, compared with whole-body imag- fibroadenomas, and benign breast tissue not otherwise spec- ing systems, holds true. ified. No studies directly compared conventional scinti- mammography with BSGI. CLINICAL INDICATIONS Initial studies introduced molecular imaging as diagnos- Annihilation Coincidence Detection Systems for tic adjuncts to conventional dedicated breast imaging using Dedicated Breast Imaging FDA-approved radiopharmaceuticals and imaging devices Several dedicated breast imaging systems for positron- with codes for potential reimbursement. However, further emitting radiopharmaceuticals have been designed (1,7). clarification of the appropriate clinical indications is needed These systems differ by the geometry and mobility of the to support their adoption into routine practice. Proposed detectors (stationary flat, rotating flat, stationary full- or indications include presurgical planning, response to ther- partial-ring) and by the positioning/immobilization of the apy monitoring, evaluation for recurrence, and adjunctive breast. The earliest design uses 2 flat detectors placed on screening for women with dense breasts. opposite sides of the breast in mild compression with the patient seated. Given that its positioning is similar to that Preoperative Evaluation of Disease Extent of mammography, this design has been termed positron- The use of imaging to guide surgical management emission mammography (PEM). An alternative design, termed (lumpectomy vs. mastectomy) involves careful evaluation dedicated breast PET, exists in which the patient is prone and of additional suggestive mammographic or sonographic the breast hangs freely through a small ring of detectors. findings with potential for additional biopsies to prove The first system to become commercially available was extent of disease. Because of its excellent sensitivity, the Flex Solo II PEM (Naviscan Inc.). It is a stationary flat dynamic contrast-enhanced breast MR imaging has been detector–based PEM scanner using limited-angle tomosyn- well-studied as an adjunctive imaging modality for surgical thetic reconstruction with an in-plane spatial resolution of planning. A recent meta-analysis revealed that MR imaging 2.4 mm, a marked improvement over whole-body PET/CT detects additional malignancy in 20% of patients, which (;5–7 mm) (9). Because images are obtained in the same included 5% in the contralateral breast (12). However, there projections as mammography with minimal breast com- remains lack of evidence demonstrating improved patient pression, correlation of imaging findings can be performed outcomes when MR imaging is used. Additionally, MR with direct coregistration possible using the earlier inte- imaging’s high sensitivity is not as equally matched by grated PEM-I design. The Flex Solo II has approval from its specificity, resulting in false-positive findings that can the FDA and has been the most extensively studied with further delay definitive treatment. multicenter trials. The potential improved specificity of dedicated breast A newer, alternative design that is commercially available molecular imaging prompted several studies comparing is MAMmography with Molecular Imaging (MAMMI) preoperative BSGI and PEM with MR imaging. Small, dedicated breast PET (Oncovision). It uses a complete ring retrospective, single-site studies using BSGI report de- of detectors for full tomographic image reconstruction with tection of additional malignancy in 9%–11% of patients, a spatial resolution of 1.6 mm (10). This system
Load more

Recommended publications
  • BREAST IMAGING for SCREENING and DIAGNOSING CANCER Policy Number: DIAGNOSTIC 105.9 T2 Effective Date: January 1, 2017
    Oxford UnitedHealthcare® Oxford Clinical Policy BREAST IMAGING FOR SCREENING AND DIAGNOSING CANCER Policy Number: DIAGNOSTIC 105.9 T2 Effective Date: January 1, 2017 Table of Contents Page Related Policies INSTRUCTIONS FOR USE .......................................... 1 Omnibus Codes CONDITIONS OF COVERAGE ...................................... 1 Preventive Care Services BENEFIT CONSIDERATIONS ...................................... 2 Radiology Procedures Requiring Precertification for COVERAGE RATIONALE ............................................. 3 eviCore Healthcare Arrangement APPLICABLE CODES ................................................. 5 DESCRIPTION OF SERVICES ...................................... 6 CLINICAL EVIDENCE ................................................. 7 U.S. FOOD AND DRUG ADMINISTRATION ................... 16 REFERENCES .......................................................... 18 POLICY HISTORY/REVISION INFORMATION ................ 22 INSTRUCTIONS FOR USE This Clinical Policy provides assistance in interpreting Oxford benefit plans. Unless otherwise stated, Oxford policies do not apply to Medicare Advantage members. Oxford reserves the right, in its sole discretion, to modify its policies as necessary. This Clinical Policy is provided for informational purposes. It does not constitute medical advice. The term Oxford includes Oxford Health Plans, LLC and all of its subsidiaries as appropriate for these policies. When deciding coverage, the member specific benefit plan document must be referenced. The terms
    [Show full text]
  • Breast Scintimammography
    CLINICAL MEDICAL POLICY Policy Name: Breast Scintimammography Policy Number: MP-105-MD-PA Responsible Department(s): Medical Management Provider Notice Date: 11/23/2020 Issue Date: 11/23/2020 Effective Date: 12/21/2020 Next Annual Review: 10/2021 Revision Date: 09/16/2020 Products: Gateway Health℠ Medicaid Application: All participating hospitals and providers Page Number(s): 1 of 5 DISCLAIMER Gateway Health℠ (Gateway) medical policy is intended to serve only as a general reference resource regarding coverage for the services described. This policy does not constitute medical advice and is not intended to govern or otherwise influence medical decisions. POLICY STATEMENT Gateway Health℠ does not provide coverage in the Company’s Medicaid products for breast scintimammography. The service is considered experimental and investigational in all applications, including but not limited to use as an adjunct to mammography or in staging the axillary lymph nodes. This policy is designed to address medical necessity guidelines that are appropriate for the majority of individuals with a particular disease, illness or condition. Each person’s unique clinical circumstances warrant individual consideration, based upon review of applicable medical records. (Current applicable Pennsylvania HealthChoices Agreement Section V. Program Requirements, B. Prior Authorization of Services, 1. General Prior Authorization Requirements.) Policy No. MP-105-MD-PA Page 1 of 5 DEFINITIONS Prior Authorization Review Panel – A panel of representatives from within the Pennsylvania Department of Human Services who have been assigned organizational responsibility for the review, approval and denial of all PH-MCO Prior Authorization policies and procedures. Scintimammography A noninvasive supplemental diagnostic testing technology that requires the use of radiopharmaceuticals in order to detect tissues within the breast that accumulate higher levels of radioactive tracer that emit gamma radiation.
    [Show full text]
  • Procedure Guideline for Breast Scintigraphy
    Procedure Guideline for Breast Scintigraphy Iraj Khalkhali, Linda E. Diggles, Raymond Taillefer, Penny R. Vandestreek, Patrick J. Peller and Hani H. Abdel-Nabi Harbor-UCLA Medical Center, Terranee; Nuclear Imaging Consultants, Roseville, California; Hospital Hôtel-Dieu de Montreal, Montreal, Quebec, Canada; Lutheran General Hospital, Park Ridge, Illinois; and University of Buffalo, Buffalo, New York Key Words: breast scintigraphy;procedureguideline should be available, as well as sonograms, if J NucíMed 1999; 40:1233-1235 obtained. 2. A breast physical examination must be performed by either the nuclear medicine physician or the PART I: PURPOSE referring physician. 3. The time of last menses and pregnancy and lactat- The purpose of this guideline is to assist nuclear medicine ing status of the patient should be determined. practitioners in recommending, performing, interpreting and reporting the results of 99mTc-sestamibi breast scintigraphy 4. Breast scintigraphy should be delayed at least 2 wk after cyst or fine-needle aspiration, and 4—6wk (mammoscintigraphy, scintimammography). after core or excisional biopsy. 5. The nuclear medicine physician should be aware of PART II: BACKGROUND INFORMATION AND DEFINITIONS physical signs and symptoms and prior surgical procedures or therapy. Breast scintigraphy is performed after intravenous admin istration of "mTc-sestamibi and includes planar and/or C. Precautions None SPECT. D. Radiopharmaceutical 1. Intravenous injection of 740-1110 MBq (20-30 PART III: COMMON INDICATIONS AND APPLICATIONS mCi) 99mTc-sestamibi should be administered in an A. Evaluate breast cancer in patients in whom mammog- arm vein contralateral to the breast with the sus raphy is not diagnostic or is difficult to interpret (e.g., pected abnormality.
    [Show full text]
  • Evaluation of Nipple Discharge
    New 2016 American College of Radiology ACR Appropriateness Criteria® Evaluation of Nipple Discharge Variant 1: Physiologic nipple discharge. Female of any age. Initial imaging examination. Radiologic Procedure Rating Comments RRL* Mammography diagnostic 1 See references [2,4-7]. ☢☢ Digital breast tomosynthesis diagnostic 1 See references [2,4-7]. ☢☢ US breast 1 See references [2,4-7]. O MRI breast without and with IV contrast 1 See references [2,4-7]. O MRI breast without IV contrast 1 See references [2,4-7]. O FDG-PEM 1 See references [2,4-7]. ☢☢☢☢ Sestamibi MBI 1 See references [2,4-7]. ☢☢☢ Ductography 1 See references [2,4-7]. ☢☢ Image-guided core biopsy breast 1 See references [2,4-7]. Varies Image-guided fine needle aspiration breast 1 Varies *Relative Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate Radiation Level Variant 2: Pathologic nipple discharge. Male or female 40 years of age or older. Initial imaging examination. Radiologic Procedure Rating Comments RRL* See references [3,6,8,10,13,14,16,25- Mammography diagnostic 9 29,32,34,42-44,71-73]. ☢☢ See references [3,6,8,10,13,14,16,25- Digital breast tomosynthesis diagnostic 9 29,32,34,42-44,71-73]. ☢☢ US is usually complementary to mammography. It can be an alternative to mammography if the patient had a recent US breast 9 mammogram or is pregnant. See O references [3,5,10,12,13,16,25,30,31,45- 49]. MRI breast without and with IV contrast 1 See references [3,8,23,24,35,46,51-55].
    [Show full text]
  • Evaluation of the Quantitative Accuracy of a Commercially-Available Positron Emission Mammography Scanner
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 8-2010 EVALUATION OF THE QUANTITATIVE ACCURACY OF A COMMERCIALLY-AVAILABLE POSITRON EMISSION MAMMOGRAPHY SCANNER Adam Springer Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Diagnosis Commons, Equipment and Supplies Commons, and the Other Medical Sciences Commons Recommended Citation Springer, Adam, "EVALUATION OF THE QUANTITATIVE ACCURACY OF A COMMERCIALLY-AVAILABLE POSITRON EMISSION MAMMOGRAPHY SCANNER" (2010). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 64. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/64 This Thesis (MS) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. EVALUATION OF THE QUANTITATIVE ACCURACY OF A COMMERCIALLY- AVAILABLE POSITRON EMISSION MAMMOGRAPHY SCANNER
    [Show full text]
  • General User Charges in AIIMS Raipur
    General User Charges in AIIMS Raipur S No. Name of General Charges Paying Ward General Remark Ward/OPD 1 Registration Charges 200 25 2 Bed Charges Per Day (Sami 2000 35 Patients being adm Deluxe) itted in 3 Bed Charges Per Day (Deluxe) 3000 35 Paying/General 4 Diet Charges Per Day 200 Optional Nil ward will pay an advance for 10 days charges at the time of admission. 5 ICU/NICU/PICU/CCU Charges 1000 (Above & 300 Per Day Over to Bed Charge 6 Minor Operation in OT/MOT 250 100 not mentioned in list, under L A 7 Minor Operation in OT/MOT 1000 300 not mentioned in list, under G A 8 Major Operation in OT, Not 2000 1000 mentioned in list under G A 9 Medical Certificate (Sickness) 10 10 10 Medical Certificate (Fitness) 10 10 11 Tubectomy / Laparoscopic 25 20 Sterilization 12 Death file charges 25 25 13 Medico Legal Injury Report 50 50 (MLR) 14 Birth / Death Certificate 1st 0 0 Copy 15 Birth / Death Certificate 5 5 Subsequent Copy 16 Additional correction in Birth 10 10 / Death / certificate 17 Completion of LIC / Insurance 50 50 claim file 18 Subsequent Pass if on special 50 50 condition 19 Supply of blood (One Unit) 250 75 1 20 Medical Board Certificate 500 500 On Special Case User Charges for Investigations in AIIMS Raipur S No. Name of Investigations Paying General Remark Ward Ward/OPD Anaesthsia 1 ABG 75 50 2 ABG ALONGWITH 150 100 ELECTROLYTES(NA+,K+)(Na,K) 3 ONLY ELECTROLYTES(Na+,K+,Cl,Ca+) 75 50 4 ONLY CALCIUM 50 25 5 GLUCOSE 25 20 6 LACTATE 25 20 7 UREA.
    [Show full text]
  • Scintimammography and Gamma Imaging of the Breast and Axilla
    MEDICAL POLICY POLICY TITLE SCINTIMAMMOGRAPHY AND GAMMA IMAGING OF THE BREAST AND AXILLA POLICY NUMBER MP-5.021 Original Issue Date (Created): 8/9/2002 Most Recent Review Date (Revised): 8/18/2020 Effective Date: 11/1/2020 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY I. POLICY Scintimammography, breast-specific gamma imaging (BSGI), and molecular breast imaging (MBI) are considered investigational in all applications, including but not limited to its use as an adjunct to mammography or in staging the axillary lymph nodes. There is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with these procedures. Use of gamma detection following radiopharmaceutical administration for localization of sentinel lymph nodes in patients with breast cancer may be considered medically necessary. Policy Guidelines The most commonly-used radiopharmaceutical in breast-specific gamma imaging or molecular breast imaging is technetium 99m (Tc-99m) sestamibi. The most commonly used radiopharmaceuticals for sentinel lymph node detection using either lymphoscintigraphy or hand-held gamma detection include Tc 99mlabeled colloids (eg, sulfur colloid). Cross-references: MP-5.022 Radioimmunoscintigraphy Imaging Monoclonal Antibody Imaging with Indium- 111 Capromab Pendetide for Prostate Cancer II. PRODUCT VARIATIONS Top This policy is only applicable to certain programs and products administered by Capital BlueCross please see additional information below, and subject to benefit variations as discussed in Section VI below. Page 1 MEDICAL POLICY POLICY TITLE SCINTIMAMMOGRAPHY AND GAMMA IMAGING OF THE BREAST AND AXILLA POLICY NUMBER MP-5.021 III. DESCRIPTION/BACKGROUND Top Scintimammography, breast-specific gamma imaging (BSGI), and molecular breast imaging (MBI) use radiotracers with nuclear medicine imaging as a diagnostic tool for abnormalities of the breast.
    [Show full text]
  • Scintimammography with a Hybrid SPECT/CT Imaging System
    ANTICANCER RESEARCH 27: 557-562 (2007) Scintimammography with a Hybrid SPECT/CT Imaging System ORAZIO SCHILLACI, ROBERTA DANIELI, LUCA FILIPPI, PASQUALE ROMANO, ELSA COSSU, CARLO MANNI and GIOVANNI SIMONETTI Department of Biopathology and Diagnostic Imaging, University "Tor Vergata", Rome, Italy Abstract. Background: Planar scintimammography is useful carcinomas are evident on mammograms, especially in dense for characterizing breast lesions >10 mm. Our aim was to or dysplastic breasts (3); moreover, its specificity and positive evaluate Tc-99m sestamibi scintimammography with a hybrid predictive value are low because it cannot always (SPECT/CT) device for functional anatomical mapping (FAM). differentiate benign lesions from malignant ones (4). The Patients and Methods: Three planar images and a chest drawbacks of mammography have led to the development of SPECT/CT were performed with a hybrid device in 53 patients complementary modalities for breast cancer imaging, with mammographically suspicious lesions. The final including scintimammography, a nuclear medicine technique histopathological diagnosis was obtained after surgery. Results: that uses radiopharmaceuticals to detect malignant breast The planar images were positive in 27 out of 37 carcinomas tumours (5, 6). Scintimammography is conventionally (sensitivity 73%) and the SPECT/CT in 33 (sensitivity 89.2%). performed with planar acquisitions, which have a low The sensitivity of planar imaging and SPECT/CT was 42.9% sensitivity for lesions ≤10 mm (5). Recently, a new imaging and 71.4% in cancers ≤10 mm, and 91.3%, and 100% in device combining a dual-head, variable angle gamma camera cancers >10 mm, respectively. The specificity was 93.8% for with a low-dose X-ray tube has been introduced (7): this both planar and SPECT/CT imaging; accuracy was 79.2% for hybrid gamma camera/CT scanner provides cross-sectional planar scans and 90.6% for SPECT/CT.
    [Show full text]
  • SNMMI Nuclear Medicine Technology Competency Based Curriculum
    Nuclear Medicine Technology Competency- Based Curriculum Guide 5th Edition Introduction Competency-based education in nuclear medicine technology focuses on those elements necessary to become an entry-level nuclear medicine technologist. Emphasizing competencies communicates entry-level knowledge, skills, attitudes, and behaviors that the nuclear medicine technology curriculum must address and that employers can expect of graduates. Competency- based education allows more flexibility in pedagogical approaches to achieve these essential competencies. The competencies are divided into eight sections: 1. Radiation Safety 2. Instrumentation, Quality Control and Quality Assurance 3. Radiopharmacy and Pharmacology 4. Diagnostic and Therapeutic Procedures 5. Patient Care 6. Professionalism and Interpersonal Communication Skills 7. Organization Systems-Based Practice 8. Research Methodology Each section lists the competencies that must be achieved by the entry level nuclear medicine technologist. The rigor of the nuclear medicine technologist entry-level competencies is such that a significant body of knowledge, skills, and experience is necessary to achieve them. This level of rigor is consistent with the Society of Nuclear Medicine and Molecular Imaging—Technologist Section’s (SNMMI-TS) recommendation that the entry-level degree for a nuclear medicine technologist should be at the baccalaureate level. The content listed under the competencies is intended to be used as a guide for what may be included in a program’s curriculum to achieve minimal competency in each area. The specific content listed should be used at the program’s discretion to meet individual curricular and accreditation needs. The content in its entirety is not considered mandatory, and other pedagogies may equally meet each program’s needs.
    [Show full text]
  • Infrequently Performed Studies in Nuclear Medicine: Part 1
    Infrequently Performed Studies in Nuclear Medicine: Part 1 Anita MacDonald and Steven Burrell Department of Diagnostic Radiology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada clinical and technical aspects of each study are discussed, Nuclear medicine is a diverse field with a large number of differ- along with a brief comparison of alternative assessment ent studies spanning virtually all organ systems and medical spe- modalities. Included in Part 1 of this article are dacroscin- cialties. Many nuclear medicine procedures are performed tigraphy, LeVeen shunts, scintimammography, right-to-left routinely; others may be performed only rarely, sometimes less (R-L) shunts, left-to-right (L-R) shunts, and heat-damaged than once per year. The infrequent nature of many studies makes it challenging to retain relevant knowledge and skills. This 2-part red blood cell (RBC) studies. Part 2 will cover cerebral article provides a review of several infrequently performed stud- spinal fluid shunt, brain death, testicular scan, quantitative ies. The topics discussed in Part 1 include dacroscintigraphy, lung perfusion scan, lymphoscintigraphy, and salivary gland LeVeen shunts, scintimammography, right-to-left shunts, left- scintigraphy studies. to-right shunts, and heat-damaged red blood cells. After reading this article, the reader should be able to list and describe the in- DACROSCINTIGRAPHY (LACRIMAL GLAND STUDY) dications for each study, list the doses and describe their proper method of administration, and describe problems that may arise The lacrimal glands are located in the lateral superior during the imaging procedure and how they should be handled. portion of each orbit.
    [Show full text]
  • Society of Nuclear Medicine Procedure Guideline for Breast Scintigraphy Version 2.0, Approved June 2, 2004
    Society of Nuclear Medicine Procedure Guideline for Breast Scintigraphy Version 2.0, approved June 2, 2004 Authors: Iraj Khalkhali, MD (Harbor-UCLA Medical Center, Torrance, CA); Gina Caravaglia, MD (Harbor-UCLA Medical Center, Torrance, CA); Hani H. Abdel-Nabi, MD, PhD (University of Buffalo, Buffalo, NY); Patrick J. Peller, MD (Woodburn Nuclear Medicine, Annandale, VA); Raymond Taillefer, MD (Hospital Hotel-Dieu de Montreal, Montreal, Quebec, Canada); Penny R. Vande Streek, DO (Sutter Roseville Medical Center, Roseville, CA); and Christophe Van de Wiele, MD (Universitair Ziekenhuis, Ghent, Belgium). I. Purpose carcinomas in patients with tissue diagnosis of breast cancer. The purpose of this guideline is to assist nuclear C. May be useful in the evaluation of the effective- medicine practitioners in recommending, performing, 99m ness of neoadjuvant chemotherapy for breast car- interpreting, and reporting the results of Tc- cinoma. sestamibi breast scintigraphy (mammoscintigraphy, scintimammography). IV. Procedure II. Background Information and Definitions A. Patient Preparation 1. No special preparation for the test is needed; Breast scintigraphy is performed after intravenous 99m however, a thorough explanation of the test administration of Tc-sestamibi and includes planar should be provided by the technologist or and/or single-photon emission computed tomography physician. Before radiopharmaceutical injec- (SPECT). tion, the technologist may have the patient at- tempt the prone position with arms extended, III. Examples of Clinical or Research to assess the feasibility of the study. Applications 2. The patient should remove all clothing and jewelry above the waist and should wear a A. Evaluate breast cancer in patients in whom hospital gown open in front.
    [Show full text]
  • BREAST IMAGING for SCREENING and DIAGNOSING CANCER Policy Number: DIAGNOSTIC 105.14 T2 Effective Date: January 1, 2018
    UnitedHealthcare® Oxford Clinical Policy BREAST IMAGING FOR SCREENING AND DIAGNOSING CANCER Policy Number: DIAGNOSTIC 105.14 T2 Effective Date: January 1, 2018 Table of Contents Page Related Policies INSTRUCTIONS FOR USE .......................................... 1 Omnibus Codes CONDITIONS OF COVERAGE ...................................... 1 Preventive Care Services BENEFIT CONSIDERATIONS ...................................... 2 Radiology Procedures Requiring Precertification for COVERAGE RATIONALE ............................................. 3 eviCore healthcare Arrangement APPLICABLE CODES ................................................. 4 DESCRIPTION OF SERVICES ...................................... 5 CLINICAL EVIDENCE ................................................. 6 U.S. FOOD AND DRUG ADMINISTRATION ................... 12 REFERENCES .......................................................... 13 POLICY HISTORY/REVISION INFORMATION ................ 16 INSTRUCTIONS FOR USE This Clinical Policy provides assistance in interpreting Oxford benefit plans. Unless otherwise stated, Oxford policies do not apply to Medicare Advantage members. Oxford reserves the right, in its sole discretion, to modify its policies as necessary. This Clinical Policy is provided for informational purposes. It does not constitute medical advice. The term Oxford includes Oxford Health Plans, LLC and all of its subsidiaries as appropriate for these policies. When deciding coverage, the member specific benefit plan document must be referenced. The terms of
    [Show full text]